CRISPR Therapeutics
CRSP
CRSP
135 hedge funds and large institutions have $855M invested in CRISPR Therapeutics in 2018 Q1 according to their latest regulatory filings, with 65 funds opening new positions, 34 increasing their positions, 26 reducing their positions, and 12 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
more funds holding
Funds holding: →
31% more repeat investments, than reductions
Existing positions increased: 34 | Existing positions reduced: 26
9.37% more ownership
Funds ownership: 30.47% → 39.84% (+9.4%)
72% less call options, than puts
Call options by funds: $8.4M | Put options by funds: $30.4M
Holders
135
Holding in Top 10
5
Calls
$8.4M
Puts
$30.4M
Top Buyers
| 1 | +$211M | |
| 2 | +$42M | |
| 3 | +$21.8M | |
| 4 |
Wells Fargo
San Francisco,
California
|
+$20.1M |
| 5 |
NMC
NEA Management Company
Timonium,
Maryland
|
+$12.1M |
Top Sellers
| 1 | -$15.1M | |
| 2 | -$12.9M | |
| 3 | -$9.76M | |
| 4 |
OM
Opaleye Management
Boston,
Massachusetts
|
-$6.6M |
| 5 |
Franklin Resources
San Mateo,
California
|
-$3.78M |